Gland Pharma Limited — Board Meeting, 05-08-2025: Outcome of Board Meeting

Gland Pharma's Board has approved its Q1 FY26 consolidated financial results. Revenue from operations rose 7% year-on-year to ₹1,505.6 Cr, with Profit After Tax (PAT) jumping 50% year-on-year to ₹215.5 Cr. Notably, its subsidiary Cenexi achieved EBITDA breakeven, marking a key turnaround. The company launched 12 new molecules in regulated markets and is aggressively expanding its GLP-1/Pen/cartridge capacity to 140 million units. R&D efforts continue robustly, with ₹46 Cr spent this quarter, and progress made in complex injectables and RTU bag pipelines.